Of the lines assayed, 23 had a copy number gain involving CCNE1 (log2 ratio > 0.3), including 11 ovarian cancer lines. ...We observed CCNE1 amplicon-dependent sensitivity to both PHA-533533 (Fig. 2A) and dinaciclib (Fig. 2B) in clonogenic survival assays. Differential effects were less apparent in short-term viability assays (Supplementary Fig. S3), with only OVCAR-3 cells showing heightened sensitivity to dinaciclib....Consistent with the survival data, the strongest effects were observed in the OVCAR-3 CCNE1-amplified cell line.